Safety and efficacy of alfuzosin 10 mg once‐daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double‐blind, placebo‐controlled studies
Authors:
Open Access
- 23 July 2003
- journal article
- clinical trial
- Published by Wiley in BJU International
- Vol. 92 (3) , 257-261
Abstract
OBJECTIVES: To examine the efficacy and safety of a once‐daily formulation of alfuzosin in a pooled analysis of three parallel, randomized, double‐blind, placebo‐controlled 3‐month studies of patients with lower urinary tract symptoms (LUTS) consistent with clinical benign prostatic hyperplasia. PATIENTS AND METHODS: Patients were randomized to receive alfuzosin, 10 mg once‐daily (473) or placebo (482) for 12 weeks. Primary efficacy criteria were improvements in the International Prostate Symptom Score (IPSS) and peak urinary flow rate (PFR). RESULTS: Alfuzosin significantly improved the mean ( sd ) IPSS, by − 6.0 (5.1) vs − 4.2 (5.7) with placebo ( P < 0.005) and the PFR, by + 2.3 (3.8) vs + 1.1 (3.1) ml/s with placebo ( P < 0.001), irrespective of prostate size. The significant improvement in LUTS included the irritative and the obstructive subscore of the IPSS and the nocturia criterion; the PFR increased rapidly and significantly, from the first visit (14 days). The quality‐of‐life score also improved significantly in alfuzosin‐treated patients. Alfuzosin was well tolerated; the number of withdrawals for adverse events was comparable in both treatment groups. The most frequently reported adverse event was dizziness (placebo 2.9%, alfuzosin 6.1%). There were no significant changes in blood pressure with alfuzosin compared with placebo, including in elderly and hypertensive patients. Sexual adverse events were rare (abnormal ejaculation, 0.6%). CONCLUSIONS: The once‐daily formulation of alfuzosin, administered at 10 mg with no dose titration is effective, with a good safety profile, especially in elderly and hypertensive patients.Keywords
This publication has 19 references indexed in Scilit:
- AlfuzosinDrugs, 2002
- Efficacy and Safety of a New Prolonged Release Formulation of Alfuzosin 10 mg Once Daily versus Alfuzosin 2.5 mg Thrice Daily and Placebo in Patients with Symptomatic Benign Prostatic HyperplasiaEuropean Urology, 2000
- A Meta-Analysis on the Efficacy and Tolerability of α1-Adrenoceptor Antagonists in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic ObstructionEuropean Urology, 1999
- Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General PracticeProstate Cancer and Prostatic Diseases, 1998
- Long-Term Evaluation of Tamsulosin in Benign Prostatic Hyperplasia: Placebo-Controlled, Double-Blind Extension of Phase III TrialUrology, 1998
- Phase III Multicenter Placebo-Controlled Study of Tamsulosin in Benign Prostatic HyperplasiaUrology, 1998
- Sustained-Release Alfuzosin, Finasteride and the Combination of Both in the Treatment of Benign Prostatic HyperplasiaEuropean Urology, 1998
- Quantification and distribution of α1‐adrenoceptor subtype mRNAs in human vas deferens: comparison with those of epididymal and pelvic portionsBritish Journal of Pharmacology, 1997
- Urinary Flow Rates in Patients with Benign Prostatic Hypertrophy following Treatment with AlfuzosinBritish Journal of Urology, 1992
- Alfuzosin for treatment of benign prostatic hypertrophyThe Lancet, 1991